Ark. judge fines J&J and unit $1.2B over Risperdal marketing

04/11/2012 | CNNMoney

An Arkansas judge said Johnson & Johnson and unit Janssen Pharmaceuticals must pay $1.2 billion for violating the state's False Claims and Deceptive Trade Practices acts in regard to marketing antipsychotic Risperdal. The penalty signals that big drugmakers "cannot lie to the FDA, patients and doctors in order to defraud Arkansas taxpayers of our Medicaid dollars," Arkansas Attorney General Dustin McDaniel said. A spokeswoman for Janssen said evidence showed the firms acted legally, and they will appeal.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Food Lawyer
Cargill
Wayzata, MN